|
Mechanismaromatase inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
中国健康受试者单次和多次口服Obicetrapib片的药代动力学、药效学和安全性的随机、平行分组、开放、单中心I期临床试验。
[Translation] A randomized, parallel-group, open-label, single-center phase I clinical trial to investigate the pharmacokinetics, pharmacodynamics, and safety of single and multiple oral administration of Obicetrapib tablets in healthy Chinese subjects.
主要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PK特征。
次要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PD特征,探索药物的剂量-暴露-效应关系;
评价中国健康受试者单次和多次口服Obicetrapib后的安全性。
[Translation] Primary purpose:
To evaluate the PK characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
Secondary purpose:
To evaluate the PD characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects, and to explore the dose-exposure-effect relationship of the drug;
To evaluate the safety of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
/ Not yet recruitingPhase 1 一项在中国超重/肥胖男性受试者中评价单次和多次Leflutrozole 口服给药后的安全性、耐受性、药代动力学和药效动力学特征的随机、双盲、安慰剂对照I期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase I clinical trial evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single and multiple oral doses of Leflutrozole in overweight/obese male subjects in China.
第一部分:超重/肥胖的健康男性受试者单次给药剂量递增研究
(1)主要目的:在超重/肥胖男性受试者中评价单次口服Leflutrozole的药代动力学(PK)特征。
(2)次要目的:在超重/肥胖男性受试者中评价单次口服Leflutrozole的安全性和耐受性。
第二部分:超重/肥胖的低促性腺激素性性腺功能减退症男性受试者多次给药研究
(1)主要目的:在超重/肥胖的低促性腺激素性性腺功能减退症男性受试者中评价多次口服Leflutrozole的药代动力学(PK)特征。
(2)次要目的:在超重/肥胖的低促性腺激素性性腺功能减退症男性受试者中评价多次口服Leflutrozole的安全性和耐受性。
[Translation] Part 1: Single-Dosage Escalation Study in Overweight/Obese Healthy Male Subjects
(1) Primary Objective: To evaluate the pharmacokinetic (PK) characteristics of a single oral dose of Leflutrozole in overweight/obese male subjects.
(2) Secondary Objective: To evaluate the safety and tolerability of a single oral dose of Leflutrozole in overweight/obese male subjects.
Part 2: Multiple-Dosage Study in Overweight/Obese Male Subjects with Hypogonadotropic Hypogonadism
(1) Primary Objective: To evaluate the pharmacokinetic (PK) characteristics of multiple oral doses of Leflutrozole in overweight/obese male subjects with hypogonadotropic hypogonadism.
(2) Secondary Objective: To evaluate the safety and tolerability of multiple oral doses of Leflutrozole in overweight/obese male subjects with hypogonadotropic hypogonadism.
100 Clinical Results associated with Pharmaron (Chengdu) Clinical Research Service Co., Ltd.
0 Patents (Medical) associated with Pharmaron (Chengdu) Clinical Research Service Co., Ltd.
100 Deals associated with Pharmaron (Chengdu) Clinical Research Service Co., Ltd.
100 Translational Medicine associated with Pharmaron (Chengdu) Clinical Research Service Co., Ltd.